drugset / Trial / NCT06235801
A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
NaSingle-groupOpen-labelTreatment
Summary
To learn the recommended dose of momelotinib that can be given in combination with gilteritinib to participants with AML.
Timeline
- Start
- 2024-05-22
- Primary completion
- 2027-10-01
- Completion
- 2029-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gilteritinib | Small molecule | — | Oral |
| Subject | Momelotinib | Small molecule | — | Oral |